lebrikizumab
Ebglyss · ATC code D11AH10
- Key facts
- Active substance
- lebrikizumab
- ATC code
- D11AH10
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Ebglyss 250 mg solution for injection in pre-filled syringe / Ebglyss 250 mg solution for injection in pre-filled pen
- Marketing authorisation holder
- Almirall, S.A.
- Information as of
- 2026-10-28
Key facts
Lebrikizumab (Ebglyss) is a monoclonal antibody against interleukin-13 used to treat moderate-to-severe atopic dermatitis in adults and adolescents.
What it is used for
- Moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older weighing at least 40 kg who are candidates for systemic therapy.
Dosing
- Induction: 500 mg (two 250 mg injections) at week 0 and week 2, then 250 mg subcutaneously every other week up to week 16.
- Consider stopping if there is no clinical response after 16 weeks; some partial responders may improve further with continued every-other-week dosing up to week 24.
- Maintenance once response is achieved: 250 mg every fourth week.
- Can be used with or without topical corticosteroids; no dose adjustment for the elderly, renal or hepatic impairment, or body weight.
- Inject into thigh or abdomen (except 5 cm around the navel) and rotate sites; self-injection possible after training.
Contraindications
- Hypersensitivity to the active substance or any excipient.
Important warnings
- Discontinue and treat if a systemic hypersensitivity reaction (immediate or delayed) occurs.
- Conjunctivitis that does not resolve with standard treatment requires ophthalmological examination.
- Treat pre-existing helminth infections before starting; stop lebrikizumab if a helminth infection does not respond to treatment until it resolves.
- Live and live attenuated vaccines should not be given concurrently.
Side effects
- Most common: conjunctivitis (6.9%), injection site reactions (2.6%), allergic conjunctivitis (1.8%) and dry eye (1.4%).
- Uncommon: herpes zoster, eosinophilia, keratitis, blepharitis.
Interactions
- No interaction studies; live vaccines should not be given concurrently with lebrikizumab.
Pregnancy and breastfeeding
- As a precaution, preferably avoid use during pregnancy.
- Breast-feeding: decide between stopping breast-feeding or therapy based on benefit for child and mother.
Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
This product has no separate US patient information.
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- EbglyssAlmirall, S.A. · EMEA/H/C/005894
Source: European Medicines Agency (EMA), product information
Brand names in 3 more European countries
- Iceland
- Ebglyss
- Liechtenstein
- Ebglyss
- Norway
- Ebglyss
EMA – Article 57 product data (EU/EEA), 2026-10-29
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Ebglyss – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/ebglyss-epar-product-information_en.pdf
Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.